Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.

Abstract: Method for producing and monitoring oral active ingredient films with a base to which a solution containing at least one active ingredient is applied, the method comprising the steps: • metering and mixing the base formulation, • coating the base formulation onto a substrate, so that a strip results • if necessary, drying the base formulation strip coated on the substrate • printing a colorant solution containing at least one active ingredient onto the upper side of the base formulation strip according to the flexographic printing method, • drying the base formulation strip coated on the substrate together with the printed active ingredient solution, • penetrating the base formulation strip coated on the substrate together with the printed active ingredient solution from the upper and/or lower side by means of radiation from a radiation source, • measuring the transmission of the penetrating radiation by means of at least one reception unit on the opposite side of the base formulation strip coated on the subs

Abstract: The invention relates to an at least three-layer transdermal therapy system (TTS), which contains, in particular, rotigotine as an active ingredient. The TTS comprises an active ingredient-containing central layer, which comprises at least one hygroscopic polymer or copolymer, an inner, active ingredient-permeable layer and an outer layer.

Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.

Abstract: The invention relates to a transdermal therapeutic system (TTS) which contains a rotigotine-containing adhesive layer and is characterized by the fact that the adhesive layer contains a hot-meltable contact adhesive. The invention also relates to the use of rotigotine for producing the adhesive layer of a TTS in a hot melt method, and a method for producing such a TTS.

Abstract: It has been found that phenyl carbamates, in particular Rivastigmine, can be formulated as a stable TTS by using a monolayer poly alkyl (meth)acrylates, wherein the poly alkyl (meth)acrylates are substantially free of free carboxylate groups.

Abstract: Method for producing and monitoring oral active ingredient films with a base to which a solution containing at least one active ingredient is applied, the method comprising the steps: • metering and mixing the base formulation, • coating the base formulation onto a substrate, so that a strip results • if necessary, drying the base formulation strip coated on the substrate • printing a colorant solution containing at least one active ingredient onto the upper side of the base formulation strip according to the flexographic printing method, • drying the base formulation strip coated on the substrate together with the printed active ingredient solution, • penetrating the base formulation strip coated on the substrate together with the printed active ingredient solution from the upper and/or lower side by means of radiation from a radiation source, • measuring the transmission of the penetrating radiation by means of at least one reception unit on the opposite side of the base formulation strip coated on the subs

Abstract: The present invention pertains to oral applicable therapeutic dosage forms, in particular to orodispersible films. The present invention especially is directed to orodispersible films comprising a base layer substantially free of therapeutically active agents and a top layer comprising the desired therapeutically active agents. The present invention also concerns suitable base layers for such orodispersible films as well as therapeutical uses thereof and methods for manufacturing them.

Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.

Abstract: A method for preparing a transdermal patch comprising a substrate layer is provided, the method comprising the steps of contacting an active pharmaceutical ingredient with a retaining means to provide a composition, applying the composition obtained in step (a) to a carrier material to form a substrate layer of the transdermal patch, wherein the retaining means remain within the final transdermal patch.

Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.

Abstract: The present invention relates to a patch containing the active ingredient rotigotine for the transdermal delivery of the active pharmaceutical agent rotigotine, comprising a backing layer (1), a matrix layer (2) containing the active ingredient, and a removable protective sheet (4) which is intended for removal before the patch is applied to the skin, characterized in that disposed with areal coverage between the matrix layer (2) and the removable protective sheet (4) is an additional interlayer (3).

Abstract: The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(?)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphtol], containing a matrix for the transdermal administration of rotigotine [(?)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1 naphtol], containing a matrix polymer which is supersaturated with a rotigotine base. Said polymer matrix is characterised in that the part of the rotigotine which is not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles having a maximum mean diameter of 30 ?m, and the matrix is free of solubilisers, crystallisation inhibitors and dispersants. The invention also relates to a flat device for the transdermal administration of rotigotine, containing the above-mentioned, preferably silicon-based polymer matrix which is supersaturated with rotigotine, and a rear layer which is impermeable to the active ingredient.

Abstract: A method for preparing a transdermal patch comprising a substrate layer is provided, the method comprising the steps of contacting an active pharmaceutical ingredient with a retaining means to provide a composition, applying the composition obtained in step (a) to a carrier material to form a substrate layer of the transdermal patch, wherein the retaining means remain within the final transdermal patch.

Abstract: This patent application relates to a transdermal therapeutic system (TTS) that comprises a Rotigotine-containing cement layer, characterized in that the cement layer contains a hot-meltable adhesive in which Rotigotine as the active substance is dispersed and partly or completely dissolved. The patent application further relates to the use of Rotigotine in the production of the cement layer of a TTS by a hot-melt method.

Abstract: The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6 alkyl, C3-10 cycloalkyl or phenyl, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium. The C atom marked with a * (star) can be present in an (R) configuration, in an (S)-configuration or a mixture thereof. The invention is characterized in that the above-mentioned compounds are free bases with a degree of purity of more than 97 wt %. The invention also relates to a method for the production of highly pure compounds of general formula (I) and to the use thereof in the production of medicaments.

Abstract: The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(?)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphtol], containing a matrix for the transdermal administration of rotigotine [(?)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1 naphtol], containing a matrix polymer which is supersaturated with a rotigotine base. Said polymer matrix is characterised in that the part of the rotigotine which is not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles having a maximum mean diameter of 30 ?m, and the matrix is free of solubilisers, crystallisation inhibitors and dispersants. The invention also relates to a flat device for the transdermal administration of rotigotine, containing the above-mentioned, preferably silicon-based polymer matrix which is supersaturated with rotigotine, and a rear layer which is impermeable to the active ingredient.

Abstract: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.

Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.

Abstract: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.